Literature DB >> 22072017

Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in mice.

Céline Lamacchia1, Emiliana Rodriguez, Gaby Palmer, Solenne Vigne, Praxedis Martin, Dominique Talabot-Ayer, Christian A Seemayer, Cem Gabay.   

Abstract

OBJECTIVES: To define the cell type (myeloid vs other cells) specific effect of interleukin 1 (IL-1) receptor antagonist (IL-1Ra) deficiency on the acute inflammatory phase of arthritis.
METHODS: Arthritis was induced by K/BxN serum transfer in wild-type (WT), IL-1Ra-deficient (IL-1Ra(-/-)) and conditional knockout mice. In the latter, IL-1Ra production was specifically targeted in myeloid cells (IL-1Ra(ΔM)) or in both hepatocytes and myeloid cells (IL-1Ra(ΔH+M)). Arthritis severity was clinically evaluated and ankle sections were scored for synovial inflammation and cartilage erosion. Quantitative RT-PCR, western blot and immunohistochemical analyses measured expression, localisation and cellular sources of the different IL-1Ra isoforms in arthritic joints.
RESULTS: Total and myeloid cell-specific IL-1Ra deficiency was associated with increased arthritis severity, although disease incidence was similar to that of WT mice. Increased clinical scores were associated with exacerbated synovial inflammation. All IL-1Ra isoforms, except for intracellular (ic)IL-1Ra2, were expressed in arthritic joints of WT mice. In contrast, production of secreted (s)IL-1Ra and icIL-1Ra3 isoforms was markedly decreased in arthritic joints of both IL-1Ra(ΔM) and IL-1Ra(ΔH+M) mice. Immunohistochemical and western blot analyses suggested that the icIL-1Ra1 isoform is produced primarily by synovial fibroblasts.
CONCLUSION: Myeloid cell-derived IL-1Ra, including both sIL-1Ra and icIL-1Ra3 isoforms, controls articular inflammation during the acute phase of K/BxN serum transfer-induced arthritis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072017     DOI: 10.1136/annrheumdis-2011-200429

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Osteoarthritis prevention through meniscal regeneration induced by intra-articular injection of meniscus stem cells.

Authors:  Weiliang Shen; Jialin Chen; Ting Zhu; Zi Yin; Xiao Chen; Longkun Chen; Zhi Fang; Boon Chin Heng; Junfeng Ji; Weishan Chen; Hong-Wei Ouyang
Journal:  Stem Cells Dev       Date:  2013-04-01       Impact factor: 3.272

2.  1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol ameliorates arthritic joints through reducing neutrophil infiltration mediated by IL-6/STAT3 and MIP-2 activation.

Authors:  Young-Jun Kim; Jae Min Shin; Su-Hyun Shin; Joo Heon Kim; Ki-Young Sohn; Heung-Jae Kim; Jong-Koo Kang; Sun Young Yoon; Jae Wha Kim
Journal:  Oncotarget       Date:  2017-07-19

3.  The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis.

Authors:  Hetal B Patel; Kristin N Kornerup; Andre' L F Sampaio; Fulvio D'Acquisto; Michael P Seed; Ana Paula Girol; Mohini Gray; Costantino Pitzalis; Sonia M Oliani; Mauro Perretti
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

4.  The severity of experimental arthritis is independent of IL-36 receptor signaling.

Authors:  Céline Lamacchia; Gaby Palmer; Emiliana Rodriguez; Praxedis Martin; Solenne Vigne; Christian A Seemayer; Dominique Talabot-Ayer; Jennifer E Towne; Cem Gabay
Journal:  Arthritis Res Ther       Date:  2013-03-01       Impact factor: 5.156

Review 5.  K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis.

Authors:  Anne D Christensen; Claus Haase; Andrew D Cook; John A Hamilton
Journal:  Front Immunol       Date:  2016-06-02       Impact factor: 7.561

6.  Pulsed electromagnetic fields potentiate the paracrine function of mesenchymal stem cells for cartilage regeneration.

Authors:  Dinesh Parate; Nurul Dinah Kadir; Cenk Celik; Eng Hin Lee; James H P Hui; Alfredo Franco-Obregón; Zheng Yang
Journal:  Stem Cell Res Ther       Date:  2020-02-03       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.